11 results on '"Buschulte, Katharina"'
Search Results
2. Disease trajectories in interstitial lung diseases – data from the EXCITING-ILD registry.
- Author
-
Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, and Höger, Philipp
- Subjects
INTERSTITIAL lung diseases ,LUNGS ,PROGRESSION-free survival ,IDIOPATHIC pulmonary fibrosis ,VITAL capacity (Respiration) ,SURVIVAL rate ,SURVIVAL analysis (Biometry) ,MULTIVARIATE analysis - Abstract
Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with different disease trajectories. Progression (PF-ILD) occurs in up to 50% of patients and is associated with increased mortality. Methods: The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for disease trajectories in different ILD. The course of disease was classified as significant (absolute forced vital capacity FVC decline > 10%) or moderate progression (FVC decline 5–10%), stable disease (FVC decline or increase < 5%) or improvement (FVC increase ≥ 5%) during time in registry. A second definition for PF-ILD included absolute decline in FVC % predicted ≥ 10% within 24 months or ≥ 1 respiratory-related hospitalisation. Risk factors for progression were determined by Cox proportional-hazard models and by logistic regression with forward selection. Kaplan-Meier curves were utilised to estimate survival time and time to progression. Results: Within the EXCITING-ILD registry 28.5% of the patients died (n = 171), mainly due to ILD (n = 71, 41.5%). Median survival time from date of diagnosis on was 15.5 years (range 0.1 to 34.4 years). From 601 included patients, progression was detected in 50.6% of the patients (n = 304) with shortest median time to progression in idiopathic NSIP (iNSIP; median 14.6 months) and idiopathic pulmonary fibrosis (IPF; median 18.9 months). Reasons for the determination as PF-ILD were mainly deterioration in lung function (PFT; 57.8%) and respiratory hospitalisations (40.6%). In multivariate analyses reduced baseline FVC together with age were significant predictors for progression (OR = 1.00, p < 0.001). Higher GAP indices were a significant risk factor for a shorter survival time (GAP stage III vs. I HR = 9.06, p < 0.001). A significant shorter survival time was found in IPF compared to sarcoidosis (HR = 0.04, p < 0.001), CTD-ILD (HR = 0.33, p < 0.001), and HP (HR = 0.30, p < 0.001). Patients with at least one reported ILD exacerbation as a reason for hospitalisation had a median survival time of 7.3 years (range 0.1 to 34.4 years) compared to 19.6 years (range 0.3 to 19.6 years) in patients without exacerbations (HR = 0.39, p < 0.001). Conclusion: Disease progression is common in all ILD and associated with increased mortality. Most important risk factors for progression are impaired baseline forced vital capacity and higher age, as well as acute exacerbations and respiratory hospitalisations for mortality. Early detection of progression remains challenging, further clinical criteria in addition to PFT might be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP).
- Author
-
Skowasch, Dirk, Bonella, Francesco, Buschulte, Katharina, Kneidinger, Nikolaus, Korsten, Peter, Kreuter, Michael, Müller-Quernheim, Joachim, Pfeifer, Michael, Prasse, Antje, Quadder, Bernd, Sander, Oliver, Schupp, Jonas C., Sitter, Helmut, Stachetzki, Bernd, and Grohé, Christian
- Published
- 2024
- Full Text
- View/download PDF
4. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.
- Author
-
Buschulte, Katharina, Kabitz, Hans-Joachim, Hagmeyer, Lars, Hammerl, Peter, Esselmann, Albert, Wiederhold, Conrad, Skowasch, Dirk, Stolpe, Christoph, Joest, Marcus, Veitshans, Stefan, Höffgen, Marc, Maqhuzu, Phillen, Schwarzkopf, Larissa, Hellmann, Andreas, Pfeifer, Michael, Behr, Jürgen, Karpavicius, Rainer, Günther, Andreas, Polke, Markus, and Höger, Philipp
- Subjects
INTERSTITIAL lung diseases ,HOSPITAL care ,CONNECTIVE tissue diseases ,PULMONARY hypertension ,PROGRESSION-free survival - Abstract
Background: Interstitial lung diseases (ILD) comprise a heterogeneous group of mainly chronic lung diseases with more than 200 entities and relevant differences in disease course and prognosis. Little data is available on hospitalisation patterns in ILD. Methods: The EXCITING-ILD (Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases) registry was analysed for hospitalisations. Reasons for hospitalisation were classified as all cause, ILD-related and respiratory hospitalisations, and patients were analysed for frequency of hospitalisations, time to first non-elective hospitalisation, mortality and progression-free survival. Additionally, the risk for hospitalisation according to GAP index and ILD subtype was calculated by Cox proportional-hazard models as well as influencing factors on prediction of hospitalisation by logistic regression with forward selection. Results: In total, 601 patients were included. 1210 hospitalisations were recorded during the 6 months prior to registry inclusion until the last study visit. 800 (66.1%) were ILD-related, 59.3% of admissions were registered in the first year after inclusion. Mortality was associated with all cause, ILD-related and respiratory-related hospitalisation. Risk factors for hospitalisation were advanced disease (GAP Index stages II and III) and CTD (connective tissue disease)-ILDs. All cause hospitalisations were associated with pulmonary hypertension (OR 2.53, p = 0.005). ILD-related hospitalisations were associated with unclassifiable ILD and concomitant emphysema (OR = 2.133, p = 0.001) as well as with other granulomatous ILDs and a positive smoking status (OR = 3.082, p = 0.005). Conclusion: Our results represent a crucial contribution in understanding predisposing factors for hospitalisation in ILD and its major impact on mortality. Further studies to characterize the most vulnerable patient group as well as approaches to prevent hospitalisations are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
- Author
-
Lederer, Christoph, Mayer, Katharina, Somogyi, Vivien, Kriegsmann, Katharina, Kriegsmann, Mark, Buschulte, Katharina, Polke, Markus, Findeisen, Peter, Herth, Felix, and Kreuter, Michael
- Subjects
BIOMARKERS ,INTERSTITIAL lung diseases ,PULMONARY function tests ,FORCED expiratory volume ,RESEARCH funding ,WHITE people ,LONGITUDINAL method - Abstract
Background: As fibrosing interstitial lung diseases (fILDs) are associated with high mortality, monitoring of disease activity under treatment is highly relevant. Krebs von den Lungen-6 (KL-6) is associated with the presence and severity of different fILDs, mainly in Asian patient populations. Objectives: Our aim was to evaluate KL-6 as a predictive biomarker in fILDs in Caucasian patients. Methods: Consecutive patients with fILDs were recruited prospectively and serum concentrations of KL-6 were measured at baseline (BL), after 6 and 12 months (6 Months, 12 Months). Clinical characteristics including pulmonary function tests were assessed at 6-monthly visits and correlated with KL-6 BL levels as well as with KL-6 level changes. Results: A total of 47 fILD patients were included (mean age: 65 years, 68% male). KL-6 levels at BL were significantly higher in fILD patients than in healthy controls (n = 44, mean age: 45, 23% male) (ILD: 1,757 ± 1960 U/mL vs. control: 265 ± 107 U/mL, p < 0.0001). However, no differences were noted between ILD subgroups. KL-6 decreased significantly under therapy (6M∆BL-KL6: −486 ± 1,505 mean U/mL, p = 0.032; 12M∆BL-KL6: −547 ± 1,782 mean U/mL, p = 0.041) and KL-6 level changes were negatively correlated with changes in pulmonary function parameters (forced vital capacity [FVC]: r = −0.562, p < 0.0001; DLCO
SB : r = −0.405, p = 0.013). While neither absolute KL-6 levels at BL nor KL-6 level changes were associated with ILD progression (FVC decline ≥10%, DLCOSB decline ≥15% or death), patients with a stable FVC showed significantly decreasing KL-6 levels (p = 0.022). Conclusions: A decline of KL-6 under therapy correlated with a clinically relevant stabilization of lung function. Thus, KL-6 might serve as a predictive biomarker, which however must be determined by larger prospective cohorts. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. How Informed Are German Patients with Pulmonary Sarcoidosis about Their Disease?
- Author
-
Buschulte, Katharina, Höger, Philipp, Ganter, Claudia, Wijsenbeek, Marlies, Kahn, Nicolas, Kriegsmann, Katharina, Wilkens, Finn Moritz, Polke, Markus, El-Hadi, Sarah, Lederer, Christoph, Herth, Felix J., and Kreuter, Michael
- Subjects
PULMONOLOGISTS ,SARCOIDOSIS ,FOCUS groups ,LUNG diseases ,AGE distribution ,RESEARCH methodology ,INTERNET ,PHYSICIAN-patient relations ,INTERVIEWING ,HEALTH literacy ,SEX distribution ,PATIENTS' attitudes ,INFORMATION resources ,HEALTH ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,SUPPORT groups ,QUALITY of life ,RESEARCH funding ,CONTENT analysis ,FATIGUE (Physiology) ,INFORMATION needs - Abstract
Background: Sarcoidosis is a multisystemic disease with a heterogenous course of disease. Comprehensive information about the complexity and treatment indications is essential for improving patient knowledge and adhering to therapy. Objectives: The aim of our study was to investigate the level and resources of information in patients with sarcoidosis and to analyze differences in patient subgroups including age and gender. Methods: We conducted a questionnaire-based online survey in Germany and three semi-structured focus group interviews. The interviews were evaluated independently by two investigators using a structured qualitative content analysis. Results: A total of 402 completed questionnaires were analyzed, 65.8% of participants were women, and the mean age was 53 years. The majority of patients felt well informed about their disease in general (59.4%), but 40.6% were inadequately informed. The most relevant information gaps related to the future perspective (70.6%) as well as fatigue and diffuse pain (63.9%). Most patients received information from their treating pulmonologist (72.1%). 94% used the internet, especially homepages of patient support groups (75.2%). Male participants more often reported being well informed about their disease and were more satisfied with the information (p = 0.001). During the interviews, patients expressed their wish for more comprehensive information and highlighted the importance of psychological co-care as well as the future perspective. Conclusions: A relevant proportion of patients with sarcoidosis are inadequately informed about their own disease, particularly with regard to factors impeding quality of life such as fatigue. Efforts are needed to improve the level and quality of information. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Interstitielle Lungenerkrankungen: Klassifikation, Differenzialdiagnostik und therapeutische Ansätze bei einer heterogenen Gruppe chronischer Lungenerkrankungen.
- Author
-
Lederer, Christoph, Buschulte, Katharina, Hellmich, Bernhard, Heußel, Claus Peter, Kriegsmann, Mark, Polke, Markus, and Kreuter, Michael
- Abstract
Copyright of Innere Medizin (2731-7080) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
8. The world of rare interstitial lung diseases.
- Author
-
Buschulte, Katharina, Cottin, Vincent, Wijsenbeek, Marlies, Kreuter, Michael, and Diesler, Rémi
- Subjects
INTERSTITIAL lung diseases ,EPIDEMIOLOGY ,PATHOGENESIS ,HEALTH outcome assessment ,PUBLIC health - Abstract
The world of rare interstitial lung diseases (ILDs) is diverse and complex. Diagnosis and therapy usually pose challenges. This review describes a selection of rare and ultrarare ILDs including pulmonary alveolar proteinosis, pulmonary alveolar microlithiasis and pleuroparenchymal fibroelastosis. In addition, monogenic ILDs or ILDs in congenital syndromes and various multiple cystic lung diseases will be discussed. All these conditions are part of the scope of the European Reference Network on rare respiratory diseases (ERN-LUNG). Epidemiology, pathogenesis, diagnostics and treatment of each disease are presented. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Entwicklung und Fortschritt bei interstitiellen Lungenerkrankungen.
- Author
-
Buschulte, Katharina, Heußel, Claus Peter, Höger, Philipp, Kahn, Nicolas, and Kreuter, Michael
- Abstract
Copyright of Wiener Klinisches Magazin is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
10. Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien).
- Author
-
Buschulte, Katharina, Hoffmann-Vold, Anna-Maria, Dobrota, Rucsandra, Höger, Philipp, Krause, Andreas, and Kreuter, Michael
- Published
- 2021
- Full Text
- View/download PDF
11. 7 Fragen an die Trägerin des «Sarkoidose-Forschungspreises» 2023.
- Author
-
Buschulte, Katharina
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.